Dr. Francesco Rinaldi studied Pharmacy at Alma Mater Studiorum - University of Bologna (Unibo). From September 2016 to March 2017 he performed the Pharmacy Internship at the Maggiore Hospital in Bologna (AUSL Bologna). In April 2017 he carried out a 3 months internship at the Italian Institute of Technology (IIT) working on the expression and the purification of proteins of pharmaceutical interest . From July 2017 to January 2018, he moved to ETH Zurich in Prof. Dario Neri Biomacromolecules group, to perform his Master Thesis, focused on the development of new monoclonal antibodies for the treatment of Acute Myeloid Leukemia. In March 2018 he graduated in Pharmacy with a final mark of 110/110 cum laude, and then in July of the same year passed the State Examination for Pharmacists with the overall mark of 292/350.
In January 2019, Dr. Rinaldi joined the Computational and Chemical Biology group at the Italian Institute of Technology first as Collaborator and then as Ph.D. Fellow thanks to the Ph.D. program in Biotechnological, Biocomputational, Pharmaceutical and Pharmacological Sciences of Unibo. In June 2023, he obtained his Ph.D. in Biotechnological, Biocomputational, Pharmaceutical and Pharmacological Sciences at Unibo, after developing his three-year work in the Computational and Chemical Biology group at the IIT, where he is currently acting as a post-doc.
Since 2021, his work has been supported by the Italian Association for Cancer Research (AIRC), thanks to a three-year fellowship.